MLC Medical LLC is pleased to announce the establishment of a strategic partnership with Prothya Biosolutions, a Netherlands-based manufacturer specializing in high-quality plasma-derived medicinal products.

As part of this collaboration, MLC Medical is expanding its portfolio with the registration of three essential therapies in the Georgian market: Human Albumin, Human Normal Immunoglobulin (IVIG), and Human Prothrombin Complex Concentrate (PCC). These products play a critical role in the management of patients requiring plasma-derived therapies, including emergency, intensive care, immunology, and coagulation-related treatments.

The partnership with Prothya Biosolutions reflects MLC Medical's ongoing commitment to introducing internationally recognized, high-quality medicines that address important healthcare needs in Georgia. By collaborating with trusted global manufacturers, we continue to strengthen our portfolio and improve patient access to advanced therapeutic solutions.

MLC Medical looks forward to a successful long-term collaboration with Prothya Biosolutions and to supporting healthcare professionals with reliable, innovative products that meet the highest standards of quality, safety, and efficacy.